Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Likun Chen

Showing results (21-30 of 123) with videos related to

Pageof 13
Sort By:
Oncotargets and Therapy|April 5, 2016
Benefit from thoracic radiotherapy in patients with extensive-disease small-cell lung cancer with elevated lactate dehydrogenaseTao Qin, Ningning Zhou, Yin-Duo Zeng, et al.
Oncoimmunology|January 3, 2024
Cerebrospinal fluid immunological cytokines predict intracranial tumor response to immunotherapy in non-small cell lung cancer patients with brain metastasesMeichen Li, Jing Chen, Hui Yu, et al.
Chemosphere|March 1, 2020
Nitrogen-doped porous carbon encapsulating iron nanoparticles for enhanced sulfathiazole removal via peroxymonosulfate activationLikun Chen, Yifei Huang, Manli Zhou, et al.
Clinical and Translational Medicine|February 26, 2021
Comparing organ-specific immune-related adverse events for immune checkpoint inhibitors: A Bayesian network meta-analysisMeichen Li, Xue Hou, Jing Chen, et al.
NPJ Precision Oncology|December 1, 2025
Efficacy and safety with aumolertinib plus anlotinib for untreated EGFR-mutant NSCLC with brain metastasesJing Chen, Yin Pan, Meichen Li, et al.
Chemical Communications (Cambridge, England)|July 9, 2016
The coupling of hemin with persistent free radicals induces a nonradical mechanism for oxidation of pollutantsBin Jiang, Dejun Dai, Yuyuan Yao, et al.
Experimental & Molecular Medicine|March 18, 2017
Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro, in vivo and ex vivoKe Yang, Yifan Chen, Kenneth Kin Wah To, et al.
Experimental & Molecular Medicine|June 20, 2020
Correction: Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro, in vivo and ex vivoKe Yang, Yifan Chen, Kenneth Kin Wah To, et al.
Lung Cancer (Amsterdam, Netherlands)|March 3, 2023
Clinical efficacy and safety of individualized pembrolizumab administration based on pharmacokinetic in advanced non-small cell lung cancer: A prospective exploratory clinical trialNa Wang, Lie Zheng, Meichen Li, et al.
Lung Cancer (Amsterdam, Netherlands)|December 20, 2024
Continuing immune checkpoint inhibitors after progression: Real-world patterns of care and outcomes in second-line treatment for extensive-stage small-cell lung cancerBaishen Zhang, Hejing Bao, Zhanquan Li, et al.
Pageof 13

Showing results (21-30 of 123) with videos related to

Sort By:
Pageof 13
Oncotargets and Therapy|April 5, 2016
Benefit from thoracic radiotherapy in patients with extensive-disease small-cell lung cancer with elevated lactate dehydrogenaseTao Qin, Ningning Zhou, Yin-Duo Zeng, et al.
Oncoimmunology|January 3, 2024
Cerebrospinal fluid immunological cytokines predict intracranial tumor response to immunotherapy in non-small cell lung cancer patients with brain metastasesMeichen Li, Jing Chen, Hui Yu, et al.
Chemosphere|March 1, 2020
Nitrogen-doped porous carbon encapsulating iron nanoparticles for enhanced sulfathiazole removal via peroxymonosulfate activationLikun Chen, Yifei Huang, Manli Zhou, et al.
Clinical and Translational Medicine|February 26, 2021
Comparing organ-specific immune-related adverse events for immune checkpoint inhibitors: A Bayesian network meta-analysisMeichen Li, Xue Hou, Jing Chen, et al.
NPJ Precision Oncology|December 1, 2025
Efficacy and safety with aumolertinib plus anlotinib for untreated EGFR-mutant NSCLC with brain metastasesJing Chen, Yin Pan, Meichen Li, et al.
Chemical Communications (Cambridge, England)|July 9, 2016
The coupling of hemin with persistent free radicals induces a nonradical mechanism for oxidation of pollutantsBin Jiang, Dejun Dai, Yuyuan Yao, et al.
Experimental & Molecular Medicine|March 18, 2017
Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro, in vivo and ex vivoKe Yang, Yifan Chen, Kenneth Kin Wah To, et al.
Experimental & Molecular Medicine|June 20, 2020
Correction: Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro, in vivo and ex vivoKe Yang, Yifan Chen, Kenneth Kin Wah To, et al.
Lung Cancer (Amsterdam, Netherlands)|March 3, 2023
Clinical efficacy and safety of individualized pembrolizumab administration based on pharmacokinetic in advanced non-small cell lung cancer: A prospective exploratory clinical trialNa Wang, Lie Zheng, Meichen Li, et al.
Lung Cancer (Amsterdam, Netherlands)|December 20, 2024
Continuing immune checkpoint inhibitors after progression: Real-world patterns of care and outcomes in second-line treatment for extensive-stage small-cell lung cancerBaishen Zhang, Hejing Bao, Zhanquan Li, et al.
Pageof 13